[Efficacy and safety of doxazosine in combination with finasteride in the treatment of prostatic adenoma].
Clinical effects and safety of doxazosine + finasteride combination were studied in patients with obstructive and irritative symptoms due to prostatic adenoma (PA). Lower urinary tract symptoms according to IPSS, size of the prostatic gland, Qmax and Qmid, bladder capacity, residual urine volume, blood pressure, PSA level, sexual function, side effects were assessed before and after combined use of the drugs in 30 patients aged 58 to 83 years (mean age 70.5 years). A significant regression of both obstructive and irritative symptoms by IPSS occurred after the treatment. Quality of life has improved. Combined treatment of PA patients has improved quality of life, urination parameters, reduced volume of residual urine. Good tolerance of the treatment was observed. Combined therapy with doxazosine and finasteride can be recommended as a basic scheme of treatment for patients with risk of PA progression.
Bogdanov
A B
AB
Luk'ianov
I V
IV
Veliev
E I
EI
D000317:Adrenergic alpha-Antagonists / Q000008:administration & dosage* / Q000009:adverse effects; D000368:Aged; D000369:Aged, 80 and over; D017292:Doxazosin / Q000008:administration & dosage* / Q000009:adverse effects; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D005260:Female; D018120:Finasteride / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000503:physiopathology / Q000652:urine; D011788:Quality of Life; D001743:Urinary Bladder / Q000378:metabolism / Q000503:physiopathology; D014554:Urination / Q000187:drug effects
D000317:Adrenergic alpha-Antagonists; D004791:Enzyme Inhibitors; D018120:Finasteride; D017292:Doxazosin